pka in 1

PKA-IN-1 is a selective and potent cyclic AMP-dependent protein kinase (PKA) catalytic subunit (cAK) inhibitor (IC50: 0.03 μM).PKA-IN-1 can be used to study diseases of the immune system.

Akt1&PKA-IN-1 is a potent dual inhibitor of Akt and PKA, with IC50 values of 0.11 μM for Akt, 0.03 μM for PKAα, and 9.8 μM for CDK2, demonstrating selective inhibition of cyclin-dependent kinase 2 (CDK2).

H1-7 (histone H1 phosphorylation site), a synthetic polypeptide, serves as a PKA substrate and demonstrates utility in various PKA substrate applications [1] [2].

Akt1&PKA-IN-2 ((R)-29), a compound specific to PKB AKT and selective for cyclin-dependent kinase 2 (CDK2), effectively inhibits AKT1, PKAa, and CDK2a with IC50 values of 0.007 µM, 0.01 µM, and 0.69 µM, respectively.

A-674563 is an orally available, ATP-competitive, and reversible inhibitor of Akt (Ki: 11 nM for Akt1) [1]. It exhibits inhibitory activity against PKA and Cdk2 (IC50: 16 46 nM) but is 10- to >1, 800-fold selective for Akt1 versus additional kinases in th

API-1 (NSC-177223) is a potent inhibitor of Akt. It induces GSK3-dependent, β-TrCP- and FBXW7-mediated Mcl-1 degradation, resulting in induction of apoptosis .

1. 8-Gingerol has antioxidant activity. 2. 8-Gingerol has antimycobacterial activity. 3. 8-Gingerol could be used as an effective skin-whitening agent. 4. 8-Gingerol shows antipyretic and anti-inflammation characteristics. 5. 8-Gingerol seems to be effect

1. Fargesin ((+/-)-Fargesin) as a potential β1AR antagonist through cAMP/PKA pathway could protect against myocardial ischemia/reperfusion injury in rats. 2. Fargesin improves dyslipidemia and hyperglycemia by activating Akt and AMPK in WAT.

st-Ht31, a cell-permeable stearated peptide derived from the amphipathic helix domain of A-kinase anchoring proteins (AKAPs), effectively binds protein kinase A (PKA), impacting PKA's cellular interactions without altering its activity. Specifically, at a 50 µM concentration, it reduces PKA's membrane anchoring in BHK-21 fibroblast reporter assays. Moreover, st-Ht31 at concentrations of 1 and 3 µM decreases both capacitance and hyperactivation in mouse sperm, thereby inhibiting in vitro fertilization. Additionally, at 50 µM, this compound facilitates cholesterol export in BHK-21 cells and RAW 264.7 macrophages expressing ATP-binding cassette transporter 1 (ABCA1), showcasing its multifaceted cellular impacts.

CL4F8-6, an ionizable cationic lipid with a pKa of 6.14, is utilized in lipid nanoparticles (LNPs) for mRNA therapeutics. When incorporated into LNPs delivering Cas9 mRNA and sgRNA, CL4F8-6 facilitates CRISPR-mediated gene knockdown in mice [1].

Malantide TFA, a synthetic dodecapeptide, originates from the phosphorylation site targeted by cAMP-dependent protein kinase (PKA) on the β-subunit of phosphorylase kinase. Exhibiting a high specificity for PKA with a Michaelis constant (Km) of 15 μM, this compound demonstrates more than 90% inhibition of substrate phosphorylation in the presence of protein inhibitor (PKI) across various rat tissue extracts [1]. Moreover, Malantide TFA acts as an effective substrate for Protein Kinase C (PKC) with a Km of 16 μM [2].

SB-747651A is a potent, ATP-competitive inhibitor of mitogen- and stress-activated kinase 1 (MSK1, IC50 = 11 nM). It targets the N-terminal kinase domain. SB-747651A inhibits MSK1, MSK2, PKA, PKB, RSK and p70S6K activity in cells.

4′-Demethylnobiletin, a bioactive metabolite, activates the PKA/ERK/CREB signaling pathway, enhances CRE-mediated transcription in hippocampal neurons, and reverses memory impairment linked to NMDA receptor antagonism through ERK signaling stimulation [1].

Bim-IN-1, a potent inhibitor of Bim expression with low toxicity, effectively reduces Bim expression levels while exhibiting minimal inhibition of protein kinase A (PKA).

PKI (14-24)amide is a potent inhibitor of Protein Kinase A (PKA), effectively inhibiting cyclic AMP-dependent protein kinase activity in cell homogenates [1] [2].

PKC412(Midostaurin (PKC412); CGP41231; CGP41251) is a broad spectrum protein kinase inhibitor. Midostaurin inhibits protein kinase C alpha (PKCalpha), vascular endothelial growth factor receptor 2 (VEGFR2), c-kit, platelet-derived growth factor receptor (PDGFR) and FMS-like tyrosine kinase 3 (FLT3) tyrosine kinases, which may result in disruption of the cell cycle, inhibition of proliferation, apoptosis, and inhibition of angiogenesis in susceptible tumors.

Paraxanthine (1,7-dimethylxanthine) is a metabolite of caffeine (sc-202514) which functions as an adenosine receptor ligand and a PARP-1 inhibitor in pulmonary epithelial cells. Studies suggest that Paraxanthine is structurally similar to caffeine and possibly mediates the physiological effects of caffeine. Also Paraxanthine acts as a competitive phosphodiesterase inhibitor, which increases intracellular cAMP, activates PKA, inhibits TNF-α and leukotriene synthesis. In addition, Paraxanthine acts as a Na+ K+ ATPase enzymatic effector.

1. Nardosinone has inhibitory effect on Ang II-induced hypertrophy in H9c2 cells, might be mediated by targeting PI3K/Akt and MEK/ERK signaling pathways. 2. Nardosinone could protect against the neuronal injury exposed to OGD, which may be relevant to the

Urocortin II, mouse, is a selective and potent endogenous peptide agonist for the type-2 corticotropin-releasing factor (CRF2) receptor, displaying K_i values of 0.66 nM for CRFR2 and >100 nM for CRFR1, signifying its high specificity. It engages CRF2 receptors through mechanisms dependent on cAMP/PKA and Ca2+/CaMKII. Additionally, Urocortin II, mouse is localized in specific regions of the central nervous system, influencing central neurons that process visceral sensory information and regulate autonomic functions [1] [2] [3].

PKI(5-24) TFA is a synthetic peptide inhibitor of PKA (cAMP-dependent protein kinase) with potent and competitive inhibition properties, exhibiting a K i of 2.3 nM. It corresponds to residues 5-24 of the natural heat-stable protein kinase inhibitor [1][2].

BBT enhances glucose-stimulated insulin secretion (GSIS) in compromised conditions, demonstrates anti-hyperglycemia effects, and shields β-cells from cytokine- or streptozotocin (STZ)-triggered apoptosis in type 2 diabetes models. Its mechanism of action involves the cAMP/PKA and long-lasting (L-type) voltage-dependent Ca2+ channel/CaMK2 pathways [1].

8-CPT-2Me-cAMP sodium is a sodium salt compound that selectively activates exchange proteins activated by cAMP (Epac), which are cAMP-sensitive guanine nucleotide exchange factors (GEFs) responsible for activating small GTPases Rap1 and Rap2. It specifically activates Epac1 with an EC50 value of 2.2 μM, while showing no activation of PKA with an EC50 value greater than 10 μM [1]. Additionally, 8-CPT-2Me-cAMP sodium stimulates the Epac-mediated release of calcium ions (Ca2+) in vitro in pancreatic β-cells [2].

Tat-AKAP79 (326-336) is a peptide that links the HIV-1 Tat protein transduction domain with an 11-amino acid sequence from A-kinase anchor protein 79 (AKAP79). This compound effectively inhibits the activation-induced sensitization by protein kinase A (PKA) or PKC of the transient receptor potential vanilloid 1 (TRPV1) at a concentration of 200 µM in isolated rat dorsal root ganglion (DRG) neurons. Additionally, it mitigates nocifensive behavior in mice elicited by formalin or phorbol 12-myristate 13-acetate (PMA014), enhances latency for paw withdrawal from radiant heat, and raises the mechanical threshold force required for paw withdrawal in a carrageenan-induced mouse model of inflammatory pain.

Lipid AX4, characterized as an ionizable cationic lipid with a pKa of 6.89, facilitates the formation of lipid nanoparticles (LNPs) for in vivo mRNA delivery [1].

PIM1-IN-4 (Compound 8) is a potent inhibitor of PIM1 and also shows significant inhibitory activity against SGK-1, PKA, CaMK-1, GSK3β, and MSK1, making it potentially valuable for cancer research [1].